Personal tragedy led Doug Evans, founder of Exton-based Kensey Nash, to change his business trajectory and become CEO of ...

Cancer treatment has long faced a challenging trade-off: therapies strong enough to eliminate tumors often cause severe side effects. One promising solution involves cytokines, natural proteins that ...

Can research into a rare, accelerated aging disease and "zombie cells" teach us something about the normal aging process?

Riverbend Water Resources District is preparing to acquire land for building a $498 million regional water treatment plant at ...

The non-alcoholic steatohepatitis (NASH) clinical trials market is estimated to generate a market size of USD 2.96 billion in ...

Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.

Following your treatment may also lower your risk of other health conditions that are more common than average in people with NASH, including other types of cancer, cardiovascular disease, and ...

GlobalData forecasts suggest that the NASH/MASH market could grow to $25.7 billion by 2032 across the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan).

The FDA has granted accelerated approval to Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced ...

With researchers anticipating 27 million cases of NASH in the U.S. by 2030, we are thrilled with this FDA approval of the first-ever medication for NASH as another tool to treat a stage of this ...

Resmetirom represents the first medication approved by the FDA to treat nonalcoholic steatohepatitis with liver fibrosis. Previously, the only treatment available was lifestyle changes aimed at ...

“NASH with fibrosis represents a serious burden for both patients and health systems. Without treatment, the disease can lead to cirrhosis, liver failure, liver cancer and premature death ...